| Item Type | Name |
|
Concept
|
Carcinoma
|
|
Concept
|
Carcinoma, Squamous Cell
|
|
Concept
|
Carcinoma, Adenosquamous
|
|
Concept
|
Carcinoma, Endometrioid
|
|
Academic Article
|
Vesicovaginal fistula formation in patients with Stage IVA cervical carcinoma.
|
|
Academic Article
|
Stage I, grade 3 endometrioid adenocarcinoma of the endometrium: an analysis of clinical outcomes and patterns of recurrence.
|
|
Academic Article
|
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasion.
|
|
Academic Article
|
Contribution of age to clinical trial enrollment and tolerance with ovarian cancer.
|
|
Academic Article
|
Multiplex profiling identifies distinct local and systemic alterations during intraperitoneal chemotherapy for ovarian cancer: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
|
|
Academic Article
|
Effect of niraparib on cardiac repolarization in patients with platinum-sensitive, recurrent epithelial ovarian, fallopian tube, and primary peritoneal cancer.
|
|
Academic Article
|
A phase 1b dose escalation study of ipafricept (OMP54F28) in combination with paclitaxel and carboplatin in patients with recurrent platinum-sensitive ovarian cancer.
|
|
Academic Article
|
PD-1 blockade in recurrent or metastatic cervical cancer: Data from cemiplimab phase I expansion cohorts and characterization of PD-L1 expression in cervical cancer.
|
|
Academic Article
|
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
|
|
Academic Article
|
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
|
|
Academic Article
|
Tamrintamab pamozirine (SC-003) in patients with platinum-resistant/refractory ovarian cancer: Findings of a phase 1 study.
|
|
Academic Article
|
Phase 1b study of anti-NaPi2b antibody-drug conjugate lifastuzumab vedotin (DNIB0600A) in patients with platinum-sensitive recurrent ovarian cancer.
|
|
Academic Article
|
Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States.
|
|
Academic Article
|
The safety and efficacy of laparoscopic surgical staging of apparent stage I ovarian and fallopian tube cancers.
|
|
Academic Article
|
A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer.
|
|
Academic Article
|
Serous fallopian tube carcinoma: a retrospective, multi-institutional case-control comparison to serous adenocarcinoma of the ovary.
|
|
Academic Article
|
Assessing the prognostic role of ATR mutation in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.
|
|
Academic Article
|
Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.
|
|
Academic Article
|
Prediction of chemotherapy response in ovarian cancer patients using a new clustered quantitative image marker.
|
|
Academic Article
|
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial.
|
|
Academic Article
|
Activity of M3814, an Oral DNA-PK Inhibitor, In Combination with Topoisomerase II Inhibitors in Ovarian Cancer Models.
|
|
Academic Article
|
Extraperitoneal para-aortic lymph node evaluation for cervical cancer via pfannenstiel incision: technique and peri-operative outcomes.
|
|
Academic Article
|
Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma.
|
|
Academic Article
|
Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
|
|
Academic Article
|
An open-label phase I dose-escalation study of the safety and pharmacokinetics of DMUC4064A in patients with platinum-resistant ovarian cancer.
|
|
Academic Article
|
Homologous recombination deficiency testing in first-line ovarian cancer.
|
|
Academic Article
|
Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer.
|
|
Academic Article
|
Clinical research in ovarian cancer: consensus recommendations from the Gynecologic Cancer InterGroup.
|